Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
#What Is The Projected Market Size Of The Primary Biliary Cholangitis Market By 2029?
The primary biliary cholangitis market size has experienced strong growth over recent years. It is set to expand from $0.98 billion in 2024 to $1.06 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.9%. The expansion observed during the historic period stems from increased disease awareness, rising global healthcare expenditure, strategic collaborations within the healthcare sector, a focus on patient advocacy, and government initiatives supporting liver health.
The primary biliary cholangitis market size is projected to experience substantial growth in the coming years, reaching $1.47 billion by 2029, at a compound annual growth rate (CAGR) of 8.6%. This anticipated expansion can be attributed to several factors, including the increasing scope of biomarker research, global initiatives in rare disease management, enhanced collaboration in clinical trials, the adoption of patient-centric healthcare approaches, and a rising demand for liver transplants. Throughout the forecast period, significant trends are expected to include further advancements in biomarker research, a greater emphasis on non-invasive diagnostic techniques, dedicated research into immunomodulatory therapies, the integration of artificial intelligence (AI), the inclusion of patient-reported outcomes in clinical trials, the expanding use of telemedicine for patient management, a focus on combination therapies, and the emergence of new treatments specifically targeting fibrosis.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13520&type=smp
Which Drivers Are Supporting Growth Of The Primary Biliary Cholangitis Market?
Rising smoking levels are anticipated to propel the growth of the primary biliary cholangitis market going forward. Smoking involves the act of inhaling and exhaling the smoke produced by burning tobacco or other substances. It is a recognized risk factor for liver diseases, including PBC, and higher smoking rates can lead to more individuals seeking medical attention for liver-related issues. For instance, in July 2023, according to Statistics Canada, a Canada-based government agency, cigarette production increased by 2.2% compared to June 2023 in Canada. Moreover, there was a 2.6% rise in cigarette sales in June, reaching 1.4 billion units compared to May. Therefore, the increase in smoking will drive the growth of the primary biliary cholangitis market.
What Are The Emerging Segments Gaining Attention In The Primary Biliary Cholangitis Market?
The primary biliary cholangitismarket covered in this report is segmented –
1) By Treatment Type: Drugs; Liver Transplantation
2) By Diagnosis: Imaging Tests; Magnetic Resonance Elastography (MRE); Magnetic Resonance Cholangiopancreatography (MRCP); Ultrasound; Fibroscan; Blood Tests; Cholesterol Test; Antibody Tests; Liver Tests; Other Diagnoses
3) By End-Users: Specialty Clinics; Homecare; Other End-Users
Subsegments:
1) By Drugs: Ursodeoxycholic Acid (UDCA); Obeticholic Acid (OCA); Fibrates; Immunosuppressive Drugs; Other Targeted Therapies
2) By Liver Transplantation: Orthotopic Liver Transplantation (OLT); Living Donor Liver Transplantation; Hepatobiliary Surgery For Liver Transplant
How Are Trends Influencing The Primary Biliary Cholangitis Market?
Companies active in the primary biliary cholangitis market are prioritizing the development of innovative and specialized treatments, such as orphan drugs featuring a combination of obeticholic acid (OCA) and bezafibrates for primary biliary cholangitis (PBC), with the goal of achieving market exclusivity. This specific combination of OCA and bezafibrate, holding an orphan drug designation, aims to present a more comprehensive and effective strategy for managing PBC treatment, potentially enhancing the quality of life for individuals affected by this rare condition. For instance, in May 2023, Intercept Pharmaceuticals, Inc., a US-based biopharmaceutical company, received orphan drug designation from the FDA for the combination of obeticholic acid (OCA) and bezafibrate, a PPAR agonist, as a potential therapy for primary biliary cholangitis (PBC), a progressive liver disease. It’s also noted that obeticholic acid (marketed as Ocaliva) is approved for PBC in the US.
Who Are The Primary Competitors In The Global Primary Biliary Cholangitis Market?
Major companies operating in the primary biliary cholangitis market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Amgen Inc., Boehringer Ingelheim International GmbH., Gilead Sciences Inc., Vertex Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac N.V., Sangamo Therapeutics Inc., Calliditas Therapeutics AB, NGM Biopharmaceuticals Inc., Bluebird Bio Inc., Intellia Therapeutics Inc., Albireo Pharma Inc., TARGET PharmaSolutions Inc., Genfit S.A., Editas Medicine Inc., CymaBay Therapeutics Inc., Ascletis Pharma Inc.
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report
Which Geographies Are Emerging As Strong Markets For The Primary Biliary Cholangitis Industry?
North America was the largest region in the primary biliary cholangitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Primary Biliary Cholangitis Market Report:
https://www.thebusinessresearchcompany.com/customise?id=13520&type=smp
Browse Through More Reports Similar to the Global Primary Biliary Cholangitis Market 2025, By The Business Research Company
Gastroesophageal Reflux Disease Gerd Global Market Report 2025
Migraine Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/migraine-global-market-report
Myelodysplastic Syndrome Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model